Daily options tracking | Bullish signals everywhere! Intel's multiple call options have doubled in premium and surged; Gold ETF trading is hot, with the call-to-put ratio climbing to 63%.
Tesla's trading volume yesterday surged 30% compared to the previous trading day, reaching 1.22 million shares. The call option chain skyrocketed to 65%. Among the options chain, the long positions occupy the main position, with the largest volume being the call option with a strike price of $235 expiring this Friday, with a volume of 0.1 million shares.
Taiwan Semiconductor's USA factory has started producing iPhone chips for Apple — A16.
Taiwan Semiconductor has begun production of Apple's iPhone chips at its foundry in Arizona. The A16 will be the first chip produced in the United States. Taiwan Semiconductor's foundry in Arizona has been under construction for several years, with planning for the project dating back to 2020. After four years of construction, the factory is now operational and has started producing chips for Apple.
Futu Morning News | Rate cut countdown! US stocks continue to break records; Bank of America: Long the seven giants of US stocks is still the most crowded trade.
"New美联储通讯社": The situation is complex, and there are still doubts about the magnitude of the Fed's first rate cut; if the Fed's first cut is done "properly", the record-breaking betting on a significant rate cut may face huge risks; Apple's iPhone 16 series pre-order sales in the first weekend fell short of expectations, analysts: the long-term outlook remains optimistic.
US stocks closed | S&P and Dow set new intraday highs, Chinese concept stocks performed well, li auto inc rose more than 12%.
In the late trading session, the US stock market saw a significant decline, but the S&P 500 index rose for the seventh consecutive day, and the Nasdaq and semiconductor index erased gains of more than 1%, with Intel rising 8% and closing up 2.7%, while Nvidia declined 1%. The Chinese concept index rose nearly 2%, and Li Auto Inc. rose more than 12%.
JPMorgan and Apple are in deep negotiations and are expected to take over the Apple credit card project from Goldman Sachs.
As Goldman Sachs decides to withdraw from the consumer finance business, Apple needs to find a new bank to take over its credit card project with over 12 million users, which is a huge customer resource for any bank. Currently, Apple is still in negotiations with JPMorgan, and due to the high-risk customers involved in Apple's credit card project, JPMorgan hopes to take over at a more favorable price. The top management of JPMorgan is paying attention to the negotiations with Apple because technology companies like Apple are challenging the traditional role of banks, and banks must consider collaborating with these technology companies.
U.S. stocks close: Fed rate cut enters countdown, S&P and Dow hit new intraday highs.
①China concept stocks rise across the board, NASDAQ China Golden Dragon Index rises by 1.83%; ②BlackRock and Microsoft plan to establish a $30 billion fund; ③Morgan Stanley negotiates with Apple, hoping to take over its credit card business; ④Musk's brain-machine company: "Blindsight" receives breakthrough medical device certification from the FDA.
Looking Into Eli Lilly's Recent Short Interest
10 Information Technology Stocks With Whale Alerts In Today's Session
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities
Stock Of The Day: Will Apple Bring The Market Down?
How much impact does the rate cut by the Federal Reserve have on the "Seven Tech Giants"?
The rate cut may not bring as much help to the 'Seven Giants' as in the past.
Biggest Even Microsoft Buyback, New Retail Sales Go Against Prevailing Wisdom, Trump Crypto Project
Unpacking the Latest Options Trading Trends in Eli Lilly
Wedbush Spotlights DELL, NVDA, MSFT, and Others as Rate Cuts Should Support the AI Trend
Dan Niles Posts On X "Expectations for $AAPL Were for AI Features to Be Able to Drive ~10%+ Y/y Growth in iPhone Sales. If Accurate, Very Early Indications Are That Sales Are Down ~10%...." "The Staggered Rollout of the AI Feature Across Geographies,...
SCMP Earlier Reporter Online Retailers In China Have Reduced Prices iPhone 16 Prices Ahead Of Its Official Release
Qualcomm Analyst Sees Opportunity In 'Regaining Share With Samsung' After Apple Revenue Squeeze
Any Concerns Over iPhone Sales Are Just a Blip in the Road for Apple: Analysts
The supply chain is in disarray, leaving investors worried about the demand for iPhone 16.
Analysts including Ming-Chi Kuo of TF International, as well as analysts from Barclays, JPMorgan, and Bank of America, have all mentioned that early data shows the iPhone 16 Pro series is below expectations. This has led to a general decline in Apple's stock and related concept stocks on Monday. Kuo stated that one of the key factors for the decrease in demand for the iPhone 16 series is that the main selling point, Apple Intelligence, was not released with the iPhone 16.
Major breakthrough in cancer treatment? Pharmaceutical companies invest billions of dollars, competing to bet on targeted radiation therapy.
Radioactive drugs have the potential to become a significant breakthrough in cancer treatment. In the past year, global pharmaceutical giants such as bristol-myers squibb, astrazeneca, and eli lilly and co have invested approximately 10 billion US dollars to actively enter the field of radioactive drugs through acquisitions and collaborations, aiming to replicate the success of Novartis in the drugs Lutathera and Pluvicto. Currently, these radioactive drugs are mainly used to treat certain types of neuroendocrine tumors and prostate cancer, with the potential to expand to the treatment of more types of cancer in the future.